Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Leo Pharma Licenses Novel Dermatology Molecules Discovered by HitGen

publication date: Nov 12, 2019

Denmark's Leo Pharma will exercise an option to develop and market a novel class of oral dermatology drugs discovered by HitGen of Chengdu. The compounds were identified by scanning HitGen’s DNA encoded libraries (DELs) to discover several novel small molecule leads for an undisclosed target specified by Leo Pharma. HitGen will be eligible for preclinical and clinical milestone payments from Leo in addition to an option exercise fee. The discovery operations were part of an ongoing collaboration between the two companies that began in 2015.  More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital